Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 4:11 pm Purchase | 2020-12-31 | 13G | Replimune Group, Inc. REPL | Redmile Group, LLC | 4,658,043 9.900% | 1,036,408 (+28.62%) | Filing History |
| 2021-02-16 4:05 pm Sale | 2020-12-31 | 13G | Replimune Group, Inc. REPL | Coffin Robert | 2,307,300 4.900% | -234,127 (-9.21%) | Filing History |
| 2021-02-16 3:15 pm Sale | 2020-12-31 | 13G | Replimune Group, Inc. REPL | Bain Capital Life Sciences Fund, L.P. | 0 0.000% | -2,575,360 (Position Closed) | Filing History |
| 2021-02-16 12:23 pm Purchase | 2020-12-31 | 13G | Replimune Group, Inc. REPL | T. Rowe Price Associates, Inc. | 2,625,691 5.700% | 2,625,691 (New Position) | Filing History |
| 2021-02-16 06:36 am Unchanged | 2020-12-31 | 13G | Replimune Group, Inc. REPL | Forbion Capital Fund III Cooperatief U.A. | 5,115,121 11.130% | 0 (Unchanged) | Filing History |
| 2021-02-11 5:12 pm Sale | 2020-12-31 | 13G | Replimune Group, Inc. REPL | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -2,309,109 (Position Closed) | Filing History |
| 2021-02-08 10:31 am Purchase | 2021-02-05 | 13G | Replimune Group, Inc. REPL | FMR LLC | 2,626,417 5.714% | 2,626,417 (New Position) | Filing History |